Lack of Seroconversion Following COVID-19 Vaccination Is an Independent Risk Factor for SARS-CoV-2 Infection in Patients With Inflammatory Bowel Disease: Data from ESCAPE-IBD, an IG-IBD Study

Le résumé fourni par la source

The introduction of SARS-CoV-2 vaccines represented the main strategy to effectively manage the consequences of Coronavirus disease 2019 (COVID-19). COVID-19 vaccines are generally recommended in patients with immune conditions and/or treated with immunosuppressive drugs.1 The clinical effectiveness of a 2-dose vaccine strategy was extensively demonstrated in patients with inflammatory bowel disease (IBD), both in terms of prevention and/or mitigation of COVID-19 and of humoral and T cell responses.2,3 These data were strengthened by studies showing high efficacy of a booster dose in restoring protection against SARS-CoV-2 infection and reducing negative clinical outcomes of COVID-19.4–7 In this evolving scenario, the interplay between antibody levels (or seroconversion) following COVID-19 vaccination and the clinical effectiveness of these vaccines is not fully understood: it is unclear whether low antibody titers are predictive per se of higher risk of breakthrough SARS-CoV-2 infections and/or severe COVID-19, as evidenced by some authors.8 Another interesting topic in IBD patients is whether immunosuppressive drugs increase the risk of SARS-CoV-2 infections and/or severe COVID-19, as shown by other reports.4,5,7

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.